A Novel Recombinant Human Collagen-based Flowable Matrix for Chronic Lower Limb Wound Management: First Results of a Clinical Trial.

Autor:	Wiser I; Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel; Department of Epidemiology and Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Tamir E; Maccabi Health Care Services, Diabetic Institute, Maccabi Hashalom, Tel Aviv, Israel., Kaufman H; Maccabi Health Care Services, Wound Clinic, Haifa, Israel., Keren E; Maccabi Health Care Services, Wound Clinic, South District, Beer Sheva, Israel., Avshalom S; Plastic and Reconstructive Surgery Department, Meir Medical Center, Kfar Saba, Israel., Klein D; Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel., Heller L; Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel., Shapira E; Department of Plastic Surgery, Assaf Harofeh Medical Center, Zerifin, Israel.
Jazyk:	angličtina
Zdroj:	Wounds : a compendium of clinical research and practice [Wounds] 2019 Apr; Vol. 31 (4), pp. 103-107. Date of Electronic Publication: 2019 Feb 14.
Abstrakt:	Background: Chronic ulcers pose a significant health concern and economic burden. Numerous products, including animal-derived collagen products, have been designed to provide the injured site with a biocompatible structural matrix that promotes tissue regeneration. Yet, animal-derived collagens can evoke immune responses, bear risk of disease transmission, and fail to closely mimic the function of native collagen. Objective: This study aims to assess the safety and performance of a novel flowable wound matrix, formulated from tobacco plant-purified fibrillated recombinant human type I collagen (rhCollagen), in patients with chronic lower limb ulcers. Materials and Methods: This single-arm, open-label, multicenter trial took place at 5 treatment centers. Wounds were photographed and preliminary surgical debridement was performed prior to rhCollagen application. Patients received a single application of rhCollagen to the wound bed, followed by weekly assessments of the wound. Results: Twenty patients (mean age, 63 years), presenting with a chronic ulcer of neuropathic (45%), posttraumatic (35%), postoperative (10%), and venous (10%) origin, underwent rhCollagen treatment. Initial wound area ranged between 0.2 cm3 to 9.2 cm3. At 4-weeks posttreatment, median wound area reduction was 94%. Fifteen ulcers exhibited ≥ 70% wound closure, 9 of which achieved complete closure. Only 1 participant suffered a local self-resolving wound infection. No significant device-related adverse events were reported throughout the study. Conclusions: A single, easy-to-use rhCollagen flowable gel application for chronic lower limb ulcers may promote wound closure with minimal adverse events.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu